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Aim: Compare efficacies of deflazacort and prednisone/prednisolone in providing clinically meaningful
delays in loss of physical milestones in patients with nonsense mutation Duchenne muscular dystrophy.
Materials & methods: Placebo data from Phase IIb (ClinicalTrials.gov Identifier: NCT00592553) and
ACT DMD (ClinicalTrials.gov Identifier: NCT01826487) ataluren nonsense mutation Duchenne muscular
dystrophy clinical trials were retrospectively combined in meta-analyses (intent-to-treat population;
for change from baseline to week 48 in 6-min walk distance [6MWD] and timed function
tests). Results: Significant improvements in change in 6-min walk distance with deflazacort versus
prednisone/prednisolone (least-squares mean difference 39.54 m [95% CI: 13.799, 65.286; p = 0.0026]).
Significant and clinically meaningful improvements in 4-stair climb and 4-stair descend for deflazacort
versus prednisone/prednisolone. Conclusion: Deflazacort provides clinically meaningful delays in loss of
physical milestones over 48 weeks compared with prednisone/prednisolone for patients with nonsense
mutation Duchenne muscular dystrophy.
First draft submitted: 22 January 2021; Accepted for publication: 2 September 2021; Published online:
25 October 2021
Keywords: deflazacort • Duchenne muscular dystrophy • meta-analysis • nonsense mutation Duchenne muscular
dystrophy • prednisolone • prednisone

Duchenne muscular dystrophy (DMD) is a rare and fatal X-linked disorder that affects one in every 3600–6000
live male births and is characterized by progressive muscle weakness and degeneration [1,2]. The current standard
of care for DMD includes treatment with the glucocorticoids prednisone, prednisolone or deflazacort [3] although
only deflazacort is currently approved by the US FDA for treating patients with DMD. Glucocorticoids used across
the lifespan of DMD patients are associated with improvements in strength and function, health-related quality of
life and survival [4]. These agents can slow the decline in muscle strength and motor function, and delay loss of
ambulation (LoA), development of scoliosis, loss of pulmonary function and cardiomyopathy [2,4–6].
The challenges of conducting a clinical trial in patients with rare diseases such as DMD include maximizing
sample sizes of patients, which is particularly important because of heterogeneity in clinical progression [7]. Metaanalyses allow for robust estimates of the effect size of an intervention based on combined evidence from individual
trials [8], and they are often employed in the study of rare diseases [9].
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However, relatively few studies have evaluated the efficacy of deflazacort versus prednisone/prednisolone directly
in the DMD population [10]. Furthermore, the available studies have used a range of different dosing regimens and
outcome measures, and included patients with varying DMD genotypes, making direct comparisons difficult.
Patients in the placebo arms of recently completed DMD trials are required to be on stable glucocorticoids
at trial entry and can continue using stable doses of glucocorticoids for the duration of the trials [10]. In a
recent meta-analysis [10] of 131 patients with varying DMD genotypes from the placebo arms of two DMD
trials [11,12], deflazacort-treated patients experienced significantly less functional decline over 48 weeks than
prednisone/prednisolone-treated patients [10].
In the present study, we assessed the efficacy of deflazacort versus prednisone/prednisolone in slowing disease
progression in a more genetically uniform population of patients with nonsense mutation DMD (nmDMD).
The current meta-analyses used data from the placebo arms of two previously published studies in patients with
nmDMD [11,13].
Patients & methods
Study inclusion criteria
R
R
We conducted a combined literature search of Ovid MEDLINE
and EMBASE
(1 January 2000–30 November
2020) to identify articles comparing deflazacort and prednisone/prednisolone in patients with DMD or nmDMD.
The search strategy is presented in Supplementary Tables 1 & 2. This search identified 11 articles comparing
deflazacort and prednisone/prednisolone in DMD. These studies included randomized trials [14–16], post hoc
analyses of placebo-arm data from industry-sponsored trials [10,17] and observational studies [4,18–22].
The identified studies included patients with different DMD genotypes, were of varying duration, used different
dosing regimens and assessed different outcomes. Only one of the 11 identified studies reported results from a randomized trial in patients with nmDMD. This was a post hoc analysis of the Phase III Ataluren Confirmatory Trial in
Duchenne Muscular Dystrophy (ACT DMD) trial (ClinicalTrials.gov Identifier: NCT01826487) that assessed the
efficacy and safety of deflazacort and prednisone/prednisolone in the placebo arm over 48 weeks [17]. However, the
authors had also available an unpublished subanalysis from the placebo arm of the Phase IIb ataluren study (ClinicalTrials.gov Identifier: NCT00592553) [13] assessing the efficacy of deflazacort versus prednisone/prednisolone.
This analysis shared common end points with the post hoc analysis of the ACT DMD trial [17]; i.e. change from
baseline in 6-minute walk distance (6MWD) and timed function tests (TFTs) over 48 weeks. We, therefore,
performed a meta-analysis on patients randomized to placebo receiving deflazacort or prednisone/prednisolone in
the ACT DMD trial and the unpublished subanalysis from the Phase IIb trial in these meta-analyses; only the end
points common to both studies are included in this report.

Study design

The two trials included were of similar design, both being randomized, double-blind, placebo-controlled, 48-week,
multicenter trials of ataluren in patients with nmDMD [11,13]. The meta-analyses included data from the placebo
arms of these studies and retrospectively analyzed data according to drug therapy initiated before the start of
the trials. Both trials enrolled boys with nmDMD, confirmed by gene sequencing, with phenotypic evidence of
dystrophinopathy, elevated serum creatine kinase levels and difficulty with ambulation. The Phase IIb trial enrolled
boys aged ≥5 years, with a 6MWD of ≥75 m at screening [13]. The inclusion criteria for the ACT DMD trial were
narrower than those of the Phase IIb trial, including boys aged ≥7 and ≤16 years, with a 6MWD of both ≥150 m
and ≤80% of that predicted for their age and height [11]. The ACT DMD trial also specified that patients should be
receiving concomitant glucocorticoid therapy at a stable dose for at least 6 months prior to study entry; this criterion
was not specified in the Phase IIb trial, but 71% of patients in that trial were receiving glucocorticoids [11,13]. Full
inclusion and exclusion criteria of the two trials have been published previously [11,13].
Data extraction

The trial sponsor analyzed the data and included all individual patient trial data from patients in both trials who
had received placebo for 48 weeks as described in the study design. The following information was collated: patient
baseline characteristics and demographics; change from baseline to week 48 in 6MWD (the primary end point
in both trials); change from baseline to week 48 in time taken to walk/run 10 m (a secondary end point in both
trials); time taken to climb 4 stairs (a secondary end point in both trials); and time taken to descend 4 stairs (a
secondary end point in both trials). The time needed to rise from the floor was not analyzed, as 15 of the 57
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(26.3%) patients in the Phase IIb study were unable to rise from the floor at baseline. These efficacy end points
were chosen because they were common to both trials. Safety outcomes, assessed throughout both trials, were also
summarized.
Data analyses

The meta-analyses were performed in compliance with the Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) 2009 guidelines, where applicable [23]. No assessment of publication bias was possible
because our meta-analysis only included two trials. These meta-analyses were performed using a fixed-effects model,
whereby for each study the point estimate was given a weight equal to the inverse of the variance of the point
estimate. We have previously used this statistical approach when assessing the efficacy of ataluren versus placebo in
a recent meta-analysis of the same two trials [24]. Outcomes for the 6-minute walk test and TFTs (10 m walk/run,
4-stair climb and 4-stair descend) are reported as the least-squares (LS) mean difference ± 95% CI [25]. The nominal
p-values for these outcomes were obtained by converting the LS mean difference to a 2-sided z-statistic [11].
The meta-analyses used only data from patients randomized to placebo in the intent-to-treat population of the
Phase IIb and ACT DMD trials. Inclusion of patients from the Phase IIb trial was restricted to those who met
the entry criteria for the ACT DMD trial (aged ≥7 and ≤16 years, diagnosed with nmDMD, with a baseline
6MWD of both ≥150 m and ≤80% of that predicted for age and height, and receiving concomitant glucocorticoid
therapy). Heterogeneity was assessed by computing the I2 statistic and the probability of there being significant
between-studies differences.
Results
Demographics & patient disposition

Baseline characteristics were well balanced between those taking deflazacort and prednisone/prednisolone in the
intent-to treat populations of both trials (Table 1). Of the 114 placebo patients from ACT DMD included in these
meta-analyses, 53 were using deflazacort and 61 were using prednisone/prednisolone. Similarly, in the Phase IIb
study, of the 40 patients in the placebo arm, 17 received deflazacort and 23 received prednisone/prednisolone. The
study participants all had a point mutation leading to a premature stop codon. The point mutations were located
in exons 1–39 for 57.9 and 59.6%, and exons 40–79 for 42.1 and 40.4% of the patients in the placebo arm of the
Phase IIb (n = 57) and ACT DMD trials (n = 114), respectively. In the Phase IIb trial, no patients discontinued
because of an adverse event (AE). In the ACT DMD trial, one patient treated with deflazacort discontinued owing
to an AE (disease progression).
Dosing

Daily dosing was the most common dosing regimen for deflazacort and prednisone/prednisolone. The mean
daily deflazacort doses were 0.785 mg/kg in the Phase IIb trial and 0.695 mg/kg in the ACT DMD trial (87.2
and 77.2% of the recommended starting dose of 0.90 mg/kg for deflazacort, respectively). The mean daily
prednisone/prednisolone doses were 0.684 mg/kg in the Phase IIb trial and 0.515 mg/kg in the ACT DMD trial
(91.2 and 68.7% of the recommended starting dose of 0.75 mg/kg for prednisone, respectively).
6MWD & TFTs

Treatment differences for the 6MWD favored deflazacort versus prednisone/prednisolone and are presented in
Figure 1. For the Phase IIb trial, the LS mean difference was 57.20 m (95% CI: 9.32, 105.08; p = 0.021); for ACT
DMD, this difference was 31.58 m (95% CI: 0.22, 62.94; p = 0.048). In the meta-analysis, the LS mean difference
was 39.54 m (95% CI: 13.80, 65.29; p = 0.0026).
Similarly, treatment differences for the 10 m walk/run favoring deflazacort over prednisone/prednisolone
were recorded for the Phase IIb trial, ACT DMD and the meta-analysis population. However, the differences
were not statistically significant (Figure 2). Treatment differences for the 4-stair climb favored deflazacort over
prednisone/prednisolone, and the differences were significant among patients from ACT DMD (2.88 s [95% CI:
0.48, 5.27; p = 0.019]) and in the meta-analysis (2.73 s [95% CI: 0.72, 4.70; p = 0.0079]; Figure 2). A statistically
significant treatment difference in the 4-stair descend also favored deflazacort over prednisone/prednisolone in the
meta-analysis (2.38 s [95% CI: 0.31, 4.46; p = 0.0244]; Figure 2).
Analyses of heterogeneity showed that between-studies differences were not statistically significant for any of the
outcomes (6MWD and TFTs).
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Table 1. Baseline patient demographics (intent-to-treat population).
Characteristic

Phase IIb

ACT DMD

Deflazacort (n = 17)

Prednisone/prednisolone
(n = 23)

Deflazacort (n = 53)

Prednisone/prednisolone (n = 61)

– Mean (SD)

9.1 (2.9)

8.3 (1.5)

9.2 (1.7)

8.8 (1.6)

– Range

6, 15

5, 11

7, 14

7, 13

– ⬍9 years

8 (47.1)

12 (52.2)

23 (43.4)

30 (49.2)

– ≥9 years

9 (52.9)

11 (47.8)

30 (56.6)

31 (50.8)

Age, years

Age group, n (%)

Race, n (%)
– White

16 (94.1)

22 (95.7)

46 (86.8)

39 (63.9)

– Black/African American

0 (0.0)

0 (0.0)

0 (0.0)

1 (1.6)

– Asian

1 (5.9)

0 (0.0)

4 (7.5)

2 (3.3)

– Hispanic

0 (0.0)

0 (0.0)

3 (5.7)

5 (8.2)

– Other

0 (0.0)

1 (4.3)

0 (0.0)

4 (6.6)

– Missing

0 (0.0)

0 (0.0)

0 (0.0)

10 (16.4)

Weight, kg
– Mean (SD)

29.9 (9.9)

31.0 (9.2)

30.9 (11.9)

30.5 (9.2)

– Range

17.9, 50.1

19.2, 54.6

18.1, 68.0

18.2, 59.8

Height, cm
– Mean (SD)

123.1 (0.2)

124.3 (10.4)

127.0 (10.6)

125.7 (10.4)

– Range

106.0, 141.0

107.0, 148.0

106.7, 148.7

101.8, 151.0

BMI, kg/m2
– Mean (SD)

19.2 (4.2)

19.7 (3.4)

18.6 (4.7)

19.0 (3.5)

– Range

14.1, 28.6

14.0, 25.6

13.0, 36.0

13.1, 27.1

Corticosteroid use prior to baseline, n (%)
– 6 to ⬍12 months

1 (5.9)

5 (21.7)

7 (13.2)

11 (18.0)

– ≥12 months

16 (94.1)

18 (78.3)

46 (86.8)

50 (82.0)

– Exons 1 to 39

9 (52.9)

14 (60.9)

36 (67.9)

32 (52.5)

– Exons 40 to 79

8 (47.1)

9 (39.1)

17 (32.1)

29 (47.5)

Location of point mutations, n (%)

ACT DMD: Ataluren Confirmatory Trial in Duchenne Muscular Dystrophy; SD: Standard deviation.

Deflazacort Prednisone/
prednisolone (n)
(n)

LS mean difference p-value
(95% CI)

Favors deflazacort

6MWD
Phase 2b trial

17

23

57.20 (9.32, 105.08)

0.021

ACT DMD

53

61

31.58 (0.22, 62.94)

0.048

Meta-analysis

70

84

39.54 (13.799, 65.286) 0.0026
-20

0

20

40

60

80

100

120

Distance (m)

Figure 1. Least-squares mean difference in change from baseline to week 48 in 6MWD. LS mean difference
presented for 6-min walk distance between patients receiving deflazacort and those receiving
prednisone/prednisone, assessed by meta-analysis of the ITT population using a fixed-effects model.
6MWD: 6-min walk distance; ACT DMD: Ataluren Confirmatory Trial in Duchenne Muscular Dystrophy; ITT:
Intent-to-treat; LS: Least-squares.
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10 m walk/run
Phase 2b trial

17

23

2.89 (-0.55, 6.32)

0.097

ACT DMD

53

61

0.09 (-1.89, 2.07)

0.930

Meta-analysis

70

84

0.82 (-0.87, 2.50)

0.3430

Phase 2b trial

17

23

2.33 (-1.64, 6.30)

0.240

ACT DMD

53

61

2.88 (0.48, 5.27)

0.019

Meta-analysis

70

84

2.73 (0.72, 4.70)

0.0079

Phase 2b trial

17

23

3.26 (-0.09, 6.62)

0.056

ACT DMD

53

61

1.77 (-0.98, 4.51)

0.204

Meta-analysis

70

84

2.38 (0.31, 4.46)

0.0244

4-stair climb

4-stair descend

-4

-2

0

2

4

6

8

Time (s)

Figure 2. Least-squares mean difference in change from baseline to week 48 in timed function tests. LS mean
differences presented for 10 m walk/run, 4-stair climb and 4-stair descend between patients receiving deflazacort and
those receiving prednisone/prednisone, assessed by meta-analyses of the ITT population using a fixed-effects model.
ACT DMD: Ataluren Confirmatory Trial in Duchenne Muscular Dystrophy; ITT: Intent-to-treat; LS: Least-squares.

Safety

The most common treatment-emergent AEs reported for the as-treated patients in these trials and for the metaanalysis patients are listed in Table 2. It should be noted that AEs reported here are from ataluren studies
and, thus, AEs associated with either glucocorticoid may be underreported. Treatment with deflazacort and
prednisone/prednisolone over the 48-week trial was generally well tolerated, and most AEs were mild to moderate
in severity. There were no discontinuations owing to AEs among patients in the Phase IIb trial. One placeboallocated patient receiving deflazacort in the ACT DMD trial discontinued because of an AE (disease progression).
There were no reports of patients in the placebo arms of either trial receiving either deflazacort or prednisone
experiencing weight gain. Mood swings were reported by one placebo-allocated patient receiving deflazacort in the
Phase IIb trial, which was resolved, and two placebo-allocated patients receiving deflazacort in the ACT DMD trial
(one was resolved and the other was recovering at the end of the trial).
Discussion
The meta-analyses of the two trials reported here showed that deflazacort conferred clinically meaningful delays
in the loss of motor function, including a statistically significant 39.5 m treatment benefit on the primary end
point of 6MWD when compared with prednisone/prednisolone over 48 weeks. We also show significant treatment
benefits with deflazacort versus prednisone/prednisolone for the secondary end points of 4-stair climb and 4-stair
descend for the intent-to-treat population. The treatment differences both exceeded the 1.5 s estimate for clinically
meaningful difference in TFTs [11,13,26].
Primary and post hoc studies of patients receiving deflazacort or prednisone/prednisolone, either in the placebo
arm or as the primary intervention, are included in Supplementary Table 3. Only two clinical trials of patients with
nmDMD were available for inclusion in these meta-analyses at the time of analysis: the ataluren Phase IIb trial and
the ACT DMD Phase III trial [11,13]. This is therefore the third time that the placebo arm of the ACT DMD Phase
III trial has been used in a post hoc analysis in order to compare deflazacort and prednisone/prednisolone [10,17].
A recent meta-analysis of two Phase III, placebo-controlled trials in DMD, reported a greater efficacy for
deflazacort than prednisone/prednisolone [10]. Like the present study, this meta-analysis also used data from the
placebo arm of the ACT DMD trial; and additionally included data from the placebo arm of a trial of tadalafil
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Table 2. Most common treatment-emergent adverse events† .
TEAE, n (%)

Phase IIb

ACT DMD

Meta-analysis population

Deflazacort (n = 17)

Prednisone/
prednisolone (n = 23)

Deflazacort (n = 53)

Prednisone/
prednisolone (n = 62)

Deflazacort (n = 70)

Prednisone/
prednisolone (n = 85)

8 (47)

5 (22)

10 (19)

11 (18)

18 (26)

16 (19)

Headache

5 (29)

7 (30)

10 (19)

11 (18)

15 (21)

18 (21)

Nasopharyngitis

5 (29)

3 (13)

6 (11)

17 (27)

11 (16)

20 (24)

Pain in extremity

3 (18)

1 (4)

6 (11)

8 (13)

9 (13)

9 (11)

Cough

4 (24)

5 (22)

5 (9)

8 (13)

9 (13)

13 (15)

Diarrhea

3 (18)

9 (39)

5 (9)

5 (8)

8 (11)

14 (16)

Pyrexia

4 (24)

3 (13)

4 (8)

8 (13)

8 (11)

11 (13)

Constipation

3 (6)

1 (4)

4 (8)

6 (10)

7 (10)

7 (8)

Influenza

3 (18)

4 (17)

3 (6)

2 (3)

6 (9)

6 (7)

Vomiting

Pain in

abdomen‡

4 (24)

3 (13)

0 (0)

18 (29)

4 (6)

21 (25)

Fall

1 (6)

3 (13)

8 (15)

12 (19)

9 (13)

15 (18)

Back pain

2 (12)

3 (13)

2 (4)

6 (10)

4 (6)

9 (11)

Nausea

1 (6)

3 (13)

3 (6)

4 (6)

4 (6)

7 (8)

Upper RTI

3 (18)

4 (17)

0 (0)

6 (10)

3 (4)

10 (7)

Gastroenteritis

1 (6)

3 (13)

2 (4)

3 (5)

3 (4)

6 (7)

Bronchitis

2 (12)

2 (9)

1 (2)

2 (3)

3 (4)

4 (5)

Rhinorrhea

2 (12)

2 (9)

1 (2)

2 (4)

3 (4)

4 (5)

Abdominal
discomfort

2 (12)

2 (9)

0 (0)

0 (0)

2 (3)

2 (2)

Dizziness

2 (12)

1 (4)

0 (0)

1 (2)

2 (3)

2 (2)

Rash

2 (12)

1 (4)

0 (0)

2 (3)

2 (3)

3 (4)

Excoriation

2 (12)

0 (0)

0 (0)

1 (2)

2 (3)

1 (1)

Procedural pain

1 (6)

6 (26)

0 (0)

0 (0)

1 (1)

6 (7)

Muscle spasms

1 (6)

4 (17)

0 (0)

1 (2)

1 (1)

4 (5)

Flatulence

1 (6)

3 (13)

0 (0)

1 (2)

1 (1)

4 (5)

Ear infection

0 (0)

4 (17)

1 (2)

0 (0)

1 (1)

4 (5)

Scar

0 (0)

3 (13)

0 (0)

0 (0)

0 (0)

3 (4)

of ≥10% in either subgroup in either trial.
upper abdomen.
ACT DMD: Ataluren Confirmatory Trial in Duchenne Muscular Dystrophy; RTI: Respiratory tract infection; TEAE: Treatment-emergent adverse event.

† Incidence
‡ Including

in patients with broad genotypes of DMD [10–12]. Approximately half of the population in that meta-analysis
had nmDMD, as only three patients with nonsense/missense mutations in the DMD gene were included from
the tadalafil study (n = 116; nonsense/missense mutation DMD; n = 3) [10–12]. The current analyses differ in
that their focus is entirely on patients with nmDMD. As is the case with the present article, the meta-analysis
recently published by McDonald and colleagues also reported a lesser decline in physical functioning among
patients treated with deflazacort compared with those treated with prednisone/prednisolone [10]. Patients treated
with deflazacort declined, on average, 28.3 m less on the 6MWD, 2.9 s less on rise from supine, 2.3 s less on
the 4-stair climb and 2.9 points less on the North Star Ambulatory Assessment linearized score than did those
treated with prednisone/prednisolone. No safety data were reported. The present meta-analysis, therefore, confirms
a treatment benefit of deflazacort compared with prednisone in a more homogenous population of patients with
nmDMD only; these results suggest that the benefit of deflazacort is evident regardless of DMD mutation type. It
could be of interest to further investigate differences in corticosteroid benefit by corticosteroid type and duration
in DMD patients stratified by other markers of disease severity aside from mutation type such as genetic modifiers,
and by stage of disease progression (i.e., early ambulatory, late ambulatory and nonambulatory phases).
Additional studies in DMD have shown greater benefits with deflazacort compared with
prednisone/prednisolone. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study, analyzing data from 340 patients with varying DMD genotypes, found that daily deflazacort treatment
significantly delayed the age at LoA by more than 2 years (median age 13.9 vs 11.2 years for those given daily
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prednisone/prednisolone) [19]. A 10-year, prospective, natural history study observed that deflazacort significantly
increased age at LoA, age at loss of supine to stand and age at loss of hand-to-mouth function when compared
with prednisone/prednisolone [4]. FOR DMD, a double-blind, randomized Phase III clinical trial investigating the
optimal glucocorticoid regimen of deflazacort or prednisone in boys aged 4–7 years old with DMD is ongoing [27].
This study aims to determine which regimen (daily deflazacort 0.9 mg/kg versus daily prednisone 0.75 mg/kg
versus intermittent prednisone 0.75 mg/kg [10 days on, 10 days off ] improves muscle strength the most and causes
the fewest side effects over 36 months; however, it should be noted that these younger patients are still making
maturational and developmental muscle gains in the absence of any glucocorticoid treatment, making it difficult
to attribute treatment effect.
Different pharmacologic properties of deflazacort versus prednisone/prednisolone [28–30], leading to greater
bioavailability of deflazacort to muscle fibers, might explain the consistent differences in efficacy observed across
the two trials included in the present meta-analysis. An alternative explanation proposed by Bello and colleagues
suggests that the differences in preservation of function are due to different adherence to care standards and/or
greater tolerance of higher dosing with deflazacort [19]. However, the dosing of glucocorticoids used (relative to
suggested dosing) was not substantially different in the two trials included in the present meta-analysis, apart
from the lower dosing per kg body weight for both glucocorticoid types in the ACT DMD trial, which might be
attributed to the older patient population enrolled. In addition, the international distribution of sites for both trials
resulted in deflazacort being readily available at the majority of sites, making differences in socio-economic status
or adherence to care standards less influential on these analyses.
The two studies included in these meta-analyses limited enrollment to patients with nmDMD. Other studies,
along with the above-mentioned meta-analysis of data from the Phase III tadalafil trial and ACT DMD, that
did not restrict enrollment according to mutation status, also observed greater efficacy with deflazacort compared
with prednisone/prednisolone for delaying loss of physical function in patients with DMD [4,10,15,21]. Of note,
McDonald et al. (2018) [4] and Marden et al. [21] were long-term studies that followed up large cohorts of patients
for at least 10 years. Another recent real-world study describing reasons for DMD and Becker muscular dystrophy
patients in the US switching from prednisone/prednisolone to deflazacort showed that physician-reported outcomes
were consistent with deflazacort addressing patients’ primary reasons for switching [31]. On the basis of these previous
findings and the known pharmacological effects of deflazacort, it is expected that ambulatory patients with DMD
caused by other types of DMD mutations would also derive greater functional benefits from deflazacort than from
prednisone/prednisolone [10–12].
The strengths of the present meta-analyses include the similarity of design of the two trials and the validity of
combining results, which was supported by the absence of statistical heterogeneity between the two trials for any of
the end points. Limitations consist of those inherent in the individual trials included in the current meta-analyses.
These include the natural history of DMD vis a vis the 48-week duration of evaluation. Current regulatory guidelines
for trials in DMD recommend a longer duration of evaluation, if possible, to evaluate long-term efficacy [32,33]. The
duration of prior treatment with glucocorticoids was not ascertained in these studies with precision. Patients in the
two trials received deflazacort or prednisone/prednisolone according to their current treatment when entering the
study [11,13]. Therefore, the meta-analyses data are not based on randomized assignment of these glucocorticoids, but
are derived from real-world use of these agents in nmDMD. Other limitations were that neither cardiomyopathy
nor pulmonary function was assessed and that there was a lack of diversity in racial composition in the two trials.
An additional limitation is that both studies were designed as ataluren trials and the AEs for each glucocorticoid in
these analyses may be underreported. Finally, these studies were confined to children with nmDMD aged 7 years
and older with a 6MWD greater than or equal to 150 m. The relative efficacy of the two glucocorticoids was not
assessed in ambulatory children younger than 7 years, in those with more severe impairment or nonambulatory
patients.
Conclusion
These meta-analyses demonstrate that, in ambulatory patients with nmDMD, deflazacort provides a clinically meaningful delay in the loss of physical functioning compared with prednisone/prednisolone, as measured by primary
and secondary end point data from two clinical trials. In these studies, deflazacort and prednisone/prednisolone
were generally well tolerated by patients with nmDMD. Future trials should assess the relative benefits of deflazacort
over a longer duration of treatment, and prespecify patient subgroups for analysis based on baseline disease severity
characteristics and length of glucocorticoid treatment.
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Summary points
• Long-term glucocorticoid treatment is a standard of care and delays the loss of physical milestones in patients
with Duchenne muscular dystrophy (DMD).
• We aimed to compare the efficacy of deflazacort and prednisone/prednisolone in providing clinically meaningful
delays in loss of physical milestones in patients with nonsense mutation Duchenne muscular dystrophy.
• Placebo data from Phase IIb (ClinicalTrials.gov Identifier: NCT00592553) and ACT DMD (ClinicalTrials.gov
Identifier: NCT01826487) ataluren nonsense mutation Duchenne muscular dystrophy clinical trials were
retrospectively combined in meta-analyses examining intent-to-treat populations of both trials.
• Placebo trial baseline demographics and characteristics were similar between the deflazacort- and
prednisone-treated patients.
• Significant improvements in change in 6-min walk distance with deflazacort versus prednisone/prednisolone
were observed.
• Significant and clinically meaningful improvements were also observed for deflazacort versus
prednisone/prednisolone for the timed function tests of 4-stair climb and 4-stair descend.
• Deflazacort provides clinically meaningful delays in loss of physical milestones compared with
prednisone/prednisolone for patients with nonsense mutation Duchenne muscular dystrophy over 48 weeks.
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